<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2676">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01502371</url>
  </required_header>
  <id_info>
    <org_study_id>P04223</org_study_id>
    <secondary_id>2008-007504-28</secondary_id>
    <secondary_id>MK-0887-086</secondary_id>
    <nct_id>NCT01502371</nct_id>
  </id_info>
  <brief_title>A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)</brief_title>
  <official_title>A 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma (Phase 2; Protocol No. P04223AM3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the dose-related efficacy, by
      evaluating morning (AM) lung function at the end of the dosing interval (AM pre-dose percent
      predicted forced expiratory volume in one second [FEV1]) across 12 weeks of treatment, of
      three doses (50 mcg, 100 mcg, and 200 mcg) of Mometasone Furoate (MF) Metered Dose Inhaler
      (MDI) twice a day (BID) compared with Placebo in children 5 to 11 years of age, inclusive,
      with persistent asthma. The primary hypothesis of this study is that at least one dose of MF
      MDI BID increases lung function, defined as a significant increase in percent predicted
      FEV1, when compared to Placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Percent Predicted Morning (AM) Forced Expiratory Volume in 1 Second (FEV1) - MF MDI vs. Placebo</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>FEV1 is the amount of air, measured in liters, forcibly exhaled in 1 second. Pulmonary function tests were to be performed by participants in the morning before dosing. The percent predicted FEV1 equals the participant's observed FEV1 divided by the participant's predicted FEV1 (determined by height and race) and converted to a percentage by multiplying by 100%. The goal of the primary outcome measure was to compare the change from Baseline in AM FEV1 between the MF MDI and Placebo treatment groups. The comparison between the MF MDI 50 mcg BID vs. MF DPI 100 mcg QD treatment groups is presented in a subsequent outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AM Peak Expiratory Flow (PEF) - MF MDI vs. Placebo</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>PEF, measured in liters per minute, is the highest flow during exhalation. Participants recorded diary entries for PEF twice daily (in the morning upon rising and in the evening at bedtime). The goal of the secondary outcome measure was to compare the change from Baseline in AM PEF between the MF MDI and Placebo treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Paediatric Asthma Quality of Life Questionnaire With Standardised Activities (PAQLQ(S)) Total Score - MF MDI vs. Placebo</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The PAQLQ(S) consists of 23 questions in 3 categories: Symptoms (10 items), Activity Limitations (5 items), and Emotional Function (8 items). Responses are based on a 7-point scale (7=not bothered at all to 1=extremely bothered). PAQLQ(S) Total Scores could range from 23 to 161, with a lower score indicating a lower quality of life. The PAQLQ(S) included only participants in participating countries in which a validated translated questionnaire was available. The goal of the secondary outcome measure was to compare the change from Baseline in PAQLQ(S) between the MF MDI and Placebo treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent Predicted AM FEV1 - MF MDI 50 mcg BID vs. MF DPI 100 mcg QD</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>FEV1 is the amount of air, measured in liters, forcibly exhaled in 1 second. Pulmonary function tests were to be performed by participants in the morning before dosing. The percent predicted FEV1 equals the participant's observed FEV1 divided by the participant's predicted FEV1 (determined by height and race) and converted to a percentage by multiplying by 100%. The goal of the secondary outcome measure was to compare the change from Baseline in AM FEV1 between the MF MDI 50 mcg BID and MF DPI 100 mcg QD treatment groups. The comparisons between the other MF MDI BID and Placebo treatment groups are presented in a previous outcome measure.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">583</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>MF MDI 50 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo dry powder inhaler (DPI) x 1 inhalation once daily (QD) in the evening for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MF MDI 100 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MF MDI 200 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MF DPI 100 mcg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg</intervention_name>
    <description>MF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks</description>
    <arm_group_label>MF MDI 50 mcg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg</intervention_name>
    <description>MF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks</description>
    <arm_group_label>MF MDI 100 mcg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg</intervention_name>
    <description>MF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks</description>
    <arm_group_label>MF MDI 200 mcg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg</intervention_name>
    <description>MF DPI 100 mcg (per inhalation), 1 puff QD for 12 weeks</description>
    <arm_group_label>MF DPI 100 mcg QD</arm_group_label>
    <other_name>Asmanex® Twisthaler®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Metered Dose Inhaler (MDI)</intervention_name>
    <description>Placebo MDI, 2 puffs BID for 12 weeks</description>
    <arm_group_label>MF DPI 100 mcg QD</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Dry Powder Inhaler (DPI)</intervention_name>
    <description>Placebo DPI, 1 puff QD for 12 weeks</description>
    <arm_group_label>MF MDI 50 mcg BID</arm_group_label>
    <arm_group_label>MF MDI 100 mcg BID</arm_group_label>
    <arm_group_label>MF MDI 200 mcg BID</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of asthma of at least 6 months duration.

          -  Using an Inhaled corticosteroid (ICS), either alone or in combination with a
             long-acting beta-2 agonist (LABA), for at least 12 weeks prior to the Screening Visit
             and must have been on a stable asthma regimen for at least 2 weeks prior to the
             Screening Visit, must not have used oral glucocorticosteroids within 30 days of the
             Screening Visit.

        Exclusion Criteria:

          -  Treated in the emergency room for a severe asthma exacerbation requiring systemic
             glucocorticosteroid treatment, or hospitalization for management of airway
             obstruction within 3 months prior to the Screening Visit.

          -  History of ventilator support for respiratory failure secondary to asthma.

          -  Upper or lower respiratory tract infection (viral or bacterial) within the 2 weeks
             prior to Screening and Baseline Visits.

          -  History of clinically significant renal, hepatic, cardiovascular, metabolic,
             neurologic, hematologic, ophthalmologic, respiratory, gastrointestinal,
             cerebrovascular, or other significant medical illness or disorder which, in the
             judgment of the investigator, could interfere with the study or require treatment
             that might interfere with the study. Specific examples include but are not limited to
             insulin-dependent diabetes, hypertension, active hepatitis, cardiovascular disease
             including hypertension, or conditions that may interfere with respiratory function
             such as, bronchiectasis, and cystic fibrosis. Other conditions that are well
             controlled and stable will not prohibit participation if deemed appropriate per the
             investigator's judgment.

          -  Inability to correctly use an oral MDI or a DPI.

          -  Participation in this study at another investigational site. Participation in a
             different investigational study at any site during the same time frame of this study.

          -  Randomization into this study more than once.

          -  Direct association with either the administration of the this study or the study
             staff.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 9, 2015</lastchanged_date>
  <firstreceived_date>December 28, 2011</firstreceived_date>
  <firstreceived_results_date>September 1, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Children</keyword>
  <keyword>Persistent</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mometasone furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 583 participants were randomized; 5 participants were randomized in error and did not receive any doses of randomized study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MF MDI 50 mcg BID</title>
          <description>Participants receive mometasone furoate (MF) metered dose inhaler (MDI) 25 mcg x 2 inhalations (50 mcg total dose) twice daily (BID) PLUS Placebo dry powder inhaler (DPI) x 1 inhalation once daily (QD) in the evening for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>MF MDI 100 mcg BID</title>
          <description>Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>MF MDI 200 mcg BID</title>
          <description>Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>MF DPI 100 mcg QD</title>
          <description>Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="125"/>
                <participants group_id="P5" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="88"/>
                <participants group_id="P5" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical Problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded Medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Baseline Analysis Population consisted of all randomized participants who received at least one dose of randomized study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>MF MDI 50 mcg BID</title>
          <description>Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>MF MDI 100 mcg BID</title>
          <description>Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>MF MDI 200 mcg BID</title>
          <description>Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>MF DPI 100 mcg QD</title>
          <description>Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="120"/>
                <measurement group_id="B2" value="113"/>
                <measurement group_id="B3" value="108"/>
                <measurement group_id="B4" value="125"/>
                <measurement group_id="B5" value="112"/>
                <measurement group_id="B6" value="578"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8.7" spread="1.7"/>
                <measurement group_id="B2" value="8.6" spread="1.9"/>
                <measurement group_id="B3" value="8.7" spread="1.7"/>
                <measurement group_id="B4" value="8.7" spread="1.7"/>
                <measurement group_id="B5" value="9.0" spread="1.7"/>
                <measurement group_id="B6" value="8.8" spread="1.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="51"/>
                <measurement group_id="B2" value="44"/>
                <measurement group_id="B3" value="59"/>
                <measurement group_id="B4" value="48"/>
                <measurement group_id="B5" value="30"/>
                <measurement group_id="B6" value="232"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
                <measurement group_id="B2" value="69"/>
                <measurement group_id="B3" value="49"/>
                <measurement group_id="B4" value="77"/>
                <measurement group_id="B5" value="82"/>
                <measurement group_id="B6" value="346"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Percent Predicted Morning (AM) Forced Expiratory Volume in 1 Second (FEV1) - MF MDI vs. Placebo</title>
        <description>FEV1 is the amount of air, measured in liters, forcibly exhaled in 1 second. Pulmonary function tests were to be performed by participants in the morning before dosing. The percent predicted FEV1 equals the participant's observed FEV1 divided by the participant's predicted FEV1 (determined by height and race) and converted to a percentage by multiplying by 100%. The goal of the primary outcome measure was to compare the change from Baseline in AM FEV1 between the MF MDI and Placebo treatment groups. The comparison between the MF MDI 50 mcg BID vs. MF DPI 100 mcg QD treatment groups is presented in a subsequent outcome measure.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Full Analysis Set (FAS) population consisted of all participants who received ≥1 study drug dose and had a Baseline or ≥1 post-randomization value for this outcome measure. Only participants who received MF MDI or Placebo were included in this primary analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MF MDI 50 mcg BID</title>
            <description>Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 200 mcg BID</title>
            <description>Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="114"/>
                  <measurement group_id="O2" value="109"/>
                  <measurement group_id="O3" value="105"/>
                  <measurement group_id="O4" value="111"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Percent Predicted Morning (AM) Forced Expiratory Volume in 1 Second (FEV1) - MF MDI vs. Placebo</title>
            <description>FEV1 is the amount of air, measured in liters, forcibly exhaled in 1 second. Pulmonary function tests were to be performed by participants in the morning before dosing. The percent predicted FEV1 equals the participant's observed FEV1 divided by the participant's predicted FEV1 (determined by height and race) and converted to a percentage by multiplying by 100%. The goal of the primary outcome measure was to compare the change from Baseline in AM FEV1 between the MF MDI and Placebo treatment groups. The comparison between the MF MDI 50 mcg BID vs. MF DPI 100 mcg QD treatment groups is presented in a subsequent outcome measure.</description>
            <units>Percentage of Predicted FEV1</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.52" lower_limit="2.32" upper_limit="6.72"/>
                  <measurement group_id="O2" value="6.95" lower_limit="4.73" upper_limit="9.16"/>
                  <measurement group_id="O3" value="6.00" lower_limit="3.74" upper_limit="8.25"/>
                  <measurement group_id="O4" value="0.66" lower_limit="-1.72" upper_limit="3.03"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline in percent predicted FEV1 at Week 12: MF MDI 50 mcg BID vs. Placebo</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.019</p_value>
            <p_value_desc>Constrained longitudinal data analysis (cLDA) model method proposed by Liang &amp; Zeger includes terms for treatment, time in weeks, age strata (age 5-6, 7-11), treatment by time interaction &amp; region (North America, Latin America &amp; the European Union)</p_value_desc>
            <method>cLDA model</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>7.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline in percent predicted FEV1 at Week 12: MF MDI 100 mcg BID vs. Placebo</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>cLDA model method proposed by Liang &amp; Zeger includes terms for treatment, time in weeks, age strata (age 5-6, 7-11), treatment by time interaction &amp; region (North America, Latin America &amp; the European Union)</p_value_desc>
            <method>cLDA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.05</ci_lower_limit>
            <ci_upper_limit>9.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline in percent predicted FEV1 at Week 12: MF MDI 200 mcg BID vs. Placebo</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.001</p_value>
            <p_value_desc>cLDA model method proposed by Liang &amp; Zeger includes terms for treatment, time in weeks, age strata (age 5-6, 7-11), treatment by time interaction &amp; region (North America, Latin America &amp; the European Union)</p_value_desc>
            <method>cLDA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.07</ci_lower_limit>
            <ci_upper_limit>8.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AM Peak Expiratory Flow (PEF) - MF MDI vs. Placebo</title>
        <description>PEF, measured in liters per minute, is the highest flow during exhalation. Participants recorded diary entries for PEF twice daily (in the morning upon rising and in the evening at bedtime). The goal of the secondary outcome measure was to compare the change from Baseline in AM PEF between the MF MDI and Placebo treatment groups.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>The FAS population consisted of all participants who received ≥1 study drug dose and had a Baseline or ≥1 post-randomization value for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MF MDI 50 mcg BID</title>
            <description>Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 200 mcg BID</title>
            <description>Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>MF DPI 100 mcg QD</title>
            <description>Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="118"/>
                  <measurement group_id="O2" value="112"/>
                  <measurement group_id="O3" value="108"/>
                  <measurement group_id="O4" value="111"/>
                  <measurement group_id="O5" value="123"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in AM Peak Expiratory Flow (PEF) - MF MDI vs. Placebo</title>
            <description>PEF, measured in liters per minute, is the highest flow during exhalation. Participants recorded diary entries for PEF twice daily (in the morning upon rising and in the evening at bedtime). The goal of the secondary outcome measure was to compare the change from Baseline in AM PEF between the MF MDI and Placebo treatment groups.</description>
            <units>Liters/minute</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17.83" lower_limit="5.35" upper_limit="30.3"/>
                  <measurement group_id="O2" value="26.03" lower_limit="13.55" upper_limit="38.51"/>
                  <measurement group_id="O3" value="16.68" lower_limit="4.50" upper_limit="28.86"/>
                  <measurement group_id="O4" value="-1.32" lower_limit="-15.49" upper_limit="12.85"/>
                  <measurement group_id="O5" value="-0.92" lower_limit="-12.82" upper_limit="10.99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline in AM PEF: MF MDI 50 mcg BID vs. Placebo. Only participants who received MF MDI or Placebo were included in the statistical analysis.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.045</p_value>
            <p_value_desc>cLDA model method proposed by Liang &amp; Zeger includes terms for treatment, time in weeks, age strata (age 5-6, 7-11), treatment by time interaction &amp; region (North America, Latin America &amp; the European Union)</p_value_desc>
            <method>cLDA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>19.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>37.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline in AM PEF: MF MDI 100 mcg BID vs. Placebo. Only participants who received MF MDI or Placebo were included in the statistical analysis.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.004</p_value>
            <p_value_desc>cLDA model method proposed by Liang &amp; Zeger includes terms for treatment, time in weeks, age strata (age 5-6, 7-11), treatment by time interaction &amp; region (North America, Latin America &amp; the European Union)</p_value_desc>
            <method>cLDA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>27.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.63</ci_lower_limit>
            <ci_upper_limit>46.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline in AM PEF: MF MDI 200 mcg BID vs. Placebo. Only participants who received MF MDI or Placebo were included in the statistical analysis.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.057</p_value>
            <p_value_desc>cLDA model method proposed by Liang &amp; Zeger includes terms for treatment, time in weeks, age strata (age 5-6, 7-11), treatment by time interaction &amp; region (North America, Latin America &amp; the European Union)</p_value_desc>
            <method>cLDA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>18.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>36.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Paediatric Asthma Quality of Life Questionnaire With Standardised Activities (PAQLQ(S)) Total Score - MF MDI vs. Placebo</title>
        <description>The PAQLQ(S) consists of 23 questions in 3 categories: Symptoms (10 items), Activity Limitations (5 items), and Emotional Function (8 items). Responses are based on a 7-point scale (7=not bothered at all to 1=extremely bothered). PAQLQ(S) Total Scores could range from 23 to 161, with a lower score indicating a lower quality of life. The PAQLQ(S) included only participants in participating countries in which a validated translated questionnaire was available. The goal of the secondary outcome measure was to compare the change from Baseline in PAQLQ(S) between the MF MDI and Placebo treatment groups.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>The FAS population consisted of all participants who received ≥1 study drug dose and had a Baseline or ≥1 post-randomization value for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MF MDI 50 mcg BID</title>
            <description>Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 100 mcg BID</title>
            <description>Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 200 mcg BID</title>
            <description>Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>MF DPI 100 mcg QD</title>
            <description>Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="111"/>
                  <measurement group_id="O2" value="105"/>
                  <measurement group_id="O3" value="101"/>
                  <measurement group_id="O4" value="102"/>
                  <measurement group_id="O5" value="115"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Paediatric Asthma Quality of Life Questionnaire With Standardised Activities (PAQLQ(S)) Total Score - MF MDI vs. Placebo</title>
            <description>The PAQLQ(S) consists of 23 questions in 3 categories: Symptoms (10 items), Activity Limitations (5 items), and Emotional Function (8 items). Responses are based on a 7-point scale (7=not bothered at all to 1=extremely bothered). PAQLQ(S) Total Scores could range from 23 to 161, with a lower score indicating a lower quality of life. The PAQLQ(S) included only participants in participating countries in which a validated translated questionnaire was available. The goal of the secondary outcome measure was to compare the change from Baseline in PAQLQ(S) between the MF MDI and Placebo treatment groups.</description>
            <units>Score on a Scale</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.35" lower_limit="0.23" upper_limit="0.48"/>
                  <measurement group_id="O2" value="0.38" lower_limit="0.25" upper_limit="0.50"/>
                  <measurement group_id="O3" value="0.44" lower_limit="0.31" upper_limit="0.56"/>
                  <measurement group_id="O4" value="0.26" lower_limit="0.12" upper_limit="0.39"/>
                  <measurement group_id="O5" value="0.47" lower_limit="0.35" upper_limit="0.59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline in PAQLQ(S) Total Score: MF MDI 50 mcg BID vs. Placebo. Only participants who received MF MDI or Placebo were included in the statistical analysis.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.280</p_value>
            <p_value_desc>cLDA model method proposed by Liang &amp; Zeger includes terms for treatment, time in weeks, age strata (age 5-6, 7-11), treatment by time interaction &amp; region (North America, Latin America &amp; the European Union)</p_value_desc>
            <method>cLDA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline in PAQLQ(S) Total Score: MF MDI 100 mcg BID vs. Placebo. Only participants who received MF MDI or Placebo were included in the statistical analysis.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.178</p_value>
            <p_value_desc>cLDA model method proposed by Liang &amp; Zeger includes terms for treatment, time in weeks, age strata (age 5-6, 7-11), treatment by time interaction &amp; region (North America, Latin America &amp; the European Union)</p_value_desc>
            <method>cLDA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline in PAQLQ(S) Total Score: MF MDI 200 mcg BID vs. Placebo. Only participants who received MF MDI or Placebo were included in the statistical analysis.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.045</p_value>
            <p_value_desc>cLDA model method proposed by Liang &amp; Zeger includes terms for treatment, time in weeks, age strata (age 5-6, 7-11), treatment by time interaction &amp; region (North America, Latin America &amp; the European Union)</p_value_desc>
            <method>cLDA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percent Predicted AM FEV1 - MF MDI 50 mcg BID vs. MF DPI 100 mcg QD</title>
        <description>FEV1 is the amount of air, measured in liters, forcibly exhaled in 1 second. Pulmonary function tests were to be performed by participants in the morning before dosing. The percent predicted FEV1 equals the participant's observed FEV1 divided by the participant's predicted FEV1 (determined by height and race) and converted to a percentage by multiplying by 100%. The goal of the secondary outcome measure was to compare the change from Baseline in AM FEV1 between the MF MDI 50 mcg BID and MF DPI 100 mcg QD treatment groups. The comparisons between the other MF MDI BID and Placebo treatment groups are presented in a previous outcome measure.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>The FAS population consisted of all participants who received ≥1 study drug dose and had a Baseline or ≥1 post-randomization value for this outcome measure. Only participants who received MF MDI 50 mcg or MF DPI were included in this secondary analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MF MDI 50 mcg BID</title>
            <description>Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>MF DPI 100 mcg QD</title>
            <description>Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="114"/>
                  <measurement group_id="O2" value="122"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Percent Predicted AM FEV1 - MF MDI 50 mcg BID vs. MF DPI 100 mcg QD</title>
            <description>FEV1 is the amount of air, measured in liters, forcibly exhaled in 1 second. Pulmonary function tests were to be performed by participants in the morning before dosing. The percent predicted FEV1 equals the participant's observed FEV1 divided by the participant's predicted FEV1 (determined by height and race) and converted to a percentage by multiplying by 100%. The goal of the secondary outcome measure was to compare the change from Baseline in AM FEV1 between the MF MDI 50 mcg BID and MF DPI 100 mcg QD treatment groups. The comparisons between the other MF MDI BID and Placebo treatment groups are presented in a previous outcome measure.</description>
            <units>Percentage of Predicted FEV1</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.52" lower_limit="2.32" upper_limit="6.72"/>
                  <measurement group_id="O2" value="3.13" lower_limit="1.01" upper_limit="5.25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline in percent predicted FEV1 at Week 12: MF MDI 50 mcg BID vs. MF DPI 100 mcg QD. Only participants who received MF MDI 50 mcg BID or MF DPI 100 mcg QD were included in the statistical analysis.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.368</p_value>
            <p_value_desc>cLDA model method proposed by Liang &amp; Zeger includes terms for treatment, time in weeks, age strata (age 5-6, 7-11), treatment by time interaction &amp; region (North America, Latin America &amp; the European Union)</p_value_desc>
            <method>cLDA model</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.65</ci_lower_limit>
            <ci_upper_limit>4.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 weeks</time_frame>
      <desc>The Safety population consisted of all participants who received at least one dose of randomized study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>MF MDI 50 mcg BID</title>
          <description>Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>MF MDI 100 mcg BID</title>
          <description>Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>MF MDI 200 mcg BID</title>
          <description>Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>MF DPI 100 mcg QD</title>
          <description>Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="125"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E3" events="19" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E4" events="14" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E5" events="19" subjects_affected="13" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
